DSIP

The DSIP evidence base cited here is 10 sources — 4 clinical, 2 preclinical, 3 review. Its strongest evidence is human — 4 clinical studies, most recently 1992 ("DSIP in Chronic Insomnia Patients"). Regulatory status: Not FDA-approved.

• DSIP is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit brain in 1974 and studied mainly for promoting deep, slow-wave sleep.
• Beyond sleep it shows broad neuromodulatory effects — stress/cortisol modulation, pain modulation, and endocrine regulation — but its exact mechanisms and clinical efficacy remain genuinely unsettled.
• It has an extraordinarily short half-life (~8 minutes), which is striking for a compound used to support an overnight effect — implying it acts as a signaling trigger rather than by sustained presence.

DSIP (Delta Sleep-Inducing Peptide) is a small endogenous neuropeptide named for its original 1974 discovery as a substance that promoted delta-wave (deep) sleep in rabbits. Decades of research since have linked it to a surprisingly wide range of neuromodulatory roles, but it has never become a defined clinical therapy — its mechanisms are still described as under investigation.

It is investigational, not FDA-approved, and everything below is research context rather than medical guidance.

DSIP is a nonapeptide — nine amino acids, sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, ~849 Da. It occurs naturally in the brain and circulates at very low levels. Unlike a sedative, it appears to work by nudging the body's own sleep machinery rather than forcing unconsciousness, which is the basis for the 'sleep without grogginess' framing in the literature.

DSIP is reported to modulate several systems at once rather than hitting a single receptor: enhancement of GABAergic (inhibitory) tone, interaction with NMDA receptors, and modulation of endogenous opioid signaling, alongside regulation of the hypothalamic-pituitary-adrenal (HPA) axis that governs the cortisol stress response. The breadth of these proposed actions — and the lack of one clean mechanism — is part of why its effects have been hard to pin down clinically.

• Time to peak: ~30 minutes
• Half-life: ~8 minutes — very short
• Largely cleared within ~40 minutes (Graf et al.)

The ~8-minute half-life is the most counterintuitive fact about DSIP: it's gone from circulation long before the overnight sleep effect it's used for, supporting the idea that it acts as a brief signaling trigger rather than through sustained exposure.

There is no approved dosing. Figures below appear in research and anecdotal use, included for research context only.

• Sleep: ~100–200 mcg once nightly, subcutaneously, ~30–60 minutes before bed
• Stress: ~150 mcg in the evening
• Research has also used IV routes for pain and withdrawal-support protocols
• Consistency of timing is commonly reported to improve results

• Reconstitute with bacteriostatic water down the vial wall; roll between the palms, don't shake; solution should be clear and colorless.
• Limited stability in solution — refrigerate immediately and use within ~14 days; protect from light and temperature swings.
• A yellow or cloudy solution indicates degradation/contamination — discard.

Generally reported as well-tolerated; some users note mild initial drowsiness or dizziness and occasional headaches. No tolerance or dependence has been reported in studies, which distinguishes it from conventional sedative-hypnotics. Avoid driving until effects are known; not recommended in pregnancy or breastfeeding. Human safety data is limited.

• Chronic insomnia, double-blind (1991, human): improved objective sleep efficiency and latency vs placebo; subjective gains were more modest.
• Endocrine modulation (1988, human/animal): modulates ACTH, cortisol, and GH release.
• Stroke recovery (2021, rats, nasal): enhanced motor recovery without reducing infarct size, suggesting a neuroprotective signaling effect.

DSIP is not FDA-approved for any indication and is sold as a research chemical for laboratory use only, not intended for human consumption.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.